Register for our free email digests:
Latest From Allecra Therapeutics GMBH
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Nosopharm SAS aims to address bacterial multidrug resistance to antibiotics, particularly in hospital-acquired gram-negative infections, using an-house drug discovery platform that exploits the microbial diversity of the bacterial genera Xenorhabdus and Photorhabdus.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging biopharma, medtech, and diagnostic life science companies that have received venture funding.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Company Type
- 1st Tier Biotech
- Parent & Subsidiaries
- Abraxis BioScience Inc.
- Acetylon Pharmaceuticals Inc.
- Avila Therapeutics Inc.
- Celgene Cellular Therapeutics
- Delinia Inc.
- EngMab AG
- Gloucester Pharmaceuticals Inc.
- Pharmion Corp.
- Quanticel Pharmaceuticals Inc.
- Receptos Inc.
- Signal Pharmaceuticals Inc.
- Senior Management
Mark Alles, CEO
Peter Kellogg, EVP, CFO
Rupert Vessey, Pres., Research & Early Dev.
Scott Smith, Pres. & COO
- Contact Info
Phone: (908) 673-9000
86 Morris Ave.
Summit, NJ 07901
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.